We leverage nucleic acid gene expression platforms to enable the patient's own cells to generate therapeutic proteins and biologics. Precisely engineered next-generation DNA plasmids and RNA oligonucleotides specify the therapeutic proteins to be produced in the context of in vivo or ex vivo treatment modalities.
Our gene expression platform technology benefits from multiple unique aspects:
At the heart of our therapies are the proteins and biologics that serve as the actual therapeutic. Our gene expression platforms are a means to specify and tune the proteins of interest: what, where, when, and how much.
Persistent and Localized
Our platform allows for the persistent expression of proteins and biologics at therapeutic levels for longer durations potentially decreasing the frequency of dosing compared to recombinant protein injections. Expression is localized when administered to target organs in vivo and produced only in specified cells when administered as ex vivo cell therapy.
The gene expression platform does not result in genomic integration unlike with viral platforms and in addition has reduced immunogenicity. Local target organ administration in vivo or ex vivo cell administration minimizes off-target dissemination and toxicity.
Resultant therapeutic proteins are generated by the patient's own cells reducing potential contaminants from manufacturing compared to recombinant proteins. Protein production by a patient's own cells additionally results in specific post-translational modifications akin to intrinsic proteins.
Up-regulation is an approach differentiated from most small molecule and biologic drugs which have been primarily utilized as inhibitors. A wealth of validated biology and accumulated knowledge exists from academic research whereby up-regulation of genes and its resultant proteins have known therapeutic effects in various disease models.
New Druggable Targets
Current drug modalities such as biologics have limitations as to what they can target due to their exogenous nature, i.e. they act outside the cell or on the surface of cells by binding to receptors. Our platform introduces new potential druggable targets by allowing for expression of cytoplasmic proteins, nuclear transcription factor proteins, expression of functional cell surface proteins, as well as secreted proteins.
Anvil Biosciences is a therapeutics engine that seeks to create novel therapeutics for indications with unmet needs.
We primarily work in the translational space evaluating discovery science, validating the biology, and creating the drug profile with continued product development into preclinical and early clinical stages.
Our target indications range from rare to large market diseases.
A far-reaching goal is to potentially utilize our platform as a drug modality that bypasses recombinant manufacturing of protein therapies by utilizing the patient's own cells to generate therapeutic proteins.
Jack Lin, Ph.D. CEO and Co-founder
Yvette Carrasco, B.S. Research Associate
Robert Place, Ph.D. Co-founder
Emily Stein, Ph.D. Co-founder
Melissa Englund, B.A. Research Associate
Our business development goals:
Leverage non-dilutive funding sources such as grants to demonstrate commercial viability validation, to de-risk the early translational research program, and to increase value proposition for subsequent investors and partners
Form research collaborations and licensing agreements with biotech and pharmaceutical partners to advance drug development
Spin out specific drug assets as holding entities for outside investment, further development, and asset-specific acquisition
Work with select investors that share a long-term perspective and are aligned with investing in Anvil Biosciences as a therapeutics engine
JULY 1, 2014
Anvil Biosciences has been awarded an SBIR grant from NIH - National Institutes of Allergy and Infectious Diseases for a therapeutics development project in neuro-inflammation
MAR. 19, 2014
Dr. Robert Place, Co-founder of Anvil Biosciences, publishes review article on non-coding RNAs: "Non-coding RNAs turn up the heat: an emerging layer of novel regulators in the mammalian heat shock response." Pubmed
MAR. 1, 2014
Anvil Biosciences has been awarded an SBIR grant from NIH - National Eye Institute for a therapeutics development project in ocular inflammation